The equity shares will be listed on the NSE as well as on the BSE.
The IPO, which opened for subscription from December 5-7, was subscribed 2.8 times at a price band of Rs 245-248 per share.
The portion set aside for qualified institutional buyers (QIBs) was subscribed 4.47 times, high net-worth individuals 43 per cent, retail investors 2.97 times and employees 1.43 times.
The initial public offer (IPO) comprised a fresh issue of shares aggregating up to Rs 480 crore and an offer for sale of up to 10 lakh equities.
In recent months, healthcare services firms like Alkem Laboratories, Dr Lal Pathlabs, Thyrocare and Eris Lifesciences have tapped the primary market through the IPO route.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
